[3-(5-Carbonochloridoyl-2-methoxyphenyl)phenyl] acetate | 1415574-61-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: [3-(5-Carbonochloridoyl-2-methoxyphenyl)phenyl] acetate
• CAS: 1415574-61-6
• 化学式: C₁₆H₁₃ClO₄
• 分子量: 304.73
• InChiKey: SKVCHHOMCNAZGB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  21
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  52.6
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  [3-(5-Carbonochloridoyl-2-methoxyphenyl)phenyl] acetate 在 吡啶 、 三乙胺 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 生成 3‘-hydroxy-6-methoxy-N-(8-methyl-7-(1-methylpiperidin-4-yloxy)-2-oxo-2H-chromen-3-yl)biphenyl-3-carboxamide
  参考文献：
  名称：

  3D-QSAR-Assisted Design, Synthesis, and Evaluation of Novobiocin Analogues

  摘要：

  Hsp90 is an attractive therapeutic target for the treatment of cancer. Extensive structural modifications to novobiocin, the first Hsp90 C-terminal inhibitor discovered, have produced a library of novobiocin analogues and revealed some structure activity relationships. On the basis of the most potent novobiocin analogues generated from prior studies, a three-dimensional quantitative structure activity (3D QSAR) model was built. In addition, a new set of novobiocin analogues containing various structural features supported by the 3D QSAR model were synthesized and evaluated against two breast cancer cell lines. Several new inhibitors produced antiproliferative activity at midnanomolar concentrations, which results through Hsp90 inhibition.

  DOI：

  10.1021/ml300275g
• 作为产物：
  描述：

  3-羟基苯硼酸 在 吡啶 、 氯化亚砜 、 bis[1,2-bis(diphenylphosphino)ferrocene]-palladium(0) 、 potassium carbonate 、 lithium hydroxide 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 甲醇 、 水 为溶剂， 生成 [3-(5-Carbonochloridoyl-2-methoxyphenyl)phenyl] acetate
  参考文献：
  名称：

  3D-QSAR-Assisted Design, Synthesis, and Evaluation of Novobiocin Analogues

  摘要：

  Hsp90 is an attractive therapeutic target for the treatment of cancer. Extensive structural modifications to novobiocin, the first Hsp90 C-terminal inhibitor discovered, have produced a library of novobiocin analogues and revealed some structure activity relationships. On the basis of the most potent novobiocin analogues generated from prior studies, a three-dimensional quantitative structure activity (3D QSAR) model was built. In addition, a new set of novobiocin analogues containing various structural features supported by the 3D QSAR model were synthesized and evaluated against two breast cancer cell lines. Several new inhibitors produced antiproliferative activity at midnanomolar concentrations, which results through Hsp90 inhibition.

  DOI：

  10.1021/ml300275g

文献信息

• Design, synthesis and biological evaluation of biphenylamide derivatives as Hsp90 C-terminal inhibitors
  作者：Huiping Zhao、Gaurav Garg、Jinbo Zhao、Elisabetta Moroni、Antwan Girgis、Lucas S. Franco、Swapnil Singh、Giorgio Colombo、Brian S.J. Blagg

  DOI：10.1016/j.ejmech.2014.10.034

  日期：2015.1

  discovery efforts toward Hsp90 C-terminal inhibition focus on novobiocin, an antibiotic that was transformed into an Hsp90 inhibitor. Based on structural information obtained during the development of novobiocin derivatives and molecular docking studies, scaffolds containing a biphenyl moiety in lieu of the coumarin ring present in novobiocin were identified as new Hsp90 C-terminal inhibitors. Structure–activity

  Hsp90 C端功能的调节代表了一种有前途的治疗方法，用于治疗癌症和神经退行性疾病。目前针对Hsp90 C末端抑制的药物发现工作集中在新霉素（一种转化为Hsp90抑制剂的抗生素）上。根据在开发新霉素衍生物和进行分子对接研究期间获得的结构信息，将含有联苯部分代替新霉素中存在的香豆素环的支架鉴定为新的Hsp90 C末端抑制剂。结构-活性关系研究产生了新的衍生物，它们以纳摩尔浓度抑制乳腺癌细胞系的增殖，这直接与Hsp90抑制作用相对应。
• [EN] BIPHENYLAMIDE DERIVATIVE HSP90 INHIBITORS<br/>[FR] INHIBITEURS DE HSP90 DÉRIVÉS DE BIPHÉNYLAMIDE
  申请人：UNIV KANSAS

  公开号：WO2015070091A1

  公开（公告）日：2015-05-14

  Compounds of the formulas are provided: wherein variables Y1-Y5, X1-X5, A1-A4, x, y, n1, n2, and R1-R15 are as defined herein. Pharmaceutical compositions of the compounds are also provided. In some aspects, these compounds are are useful for the treatment of a disease or disorder, including, for example, a proliferative disease, such as cancer.

  提供具有以下公式的化合物：其中变量Y1-Y5、X1-X5、A1-A4、x、y、n1、n2和R1-R15按本文定义。还提供了这些化合物的药物组合物。在某些方面，这些化合物对于治疗一种疾病或失调，包括例如增殖性疾病（如癌症）是有用的。
• BIPHENYLAMIDE DERIVATIVE HSP90 INHIBITORS
  申请人：THE UNIVERSITY OF KANSAS

  公开号：US20160272584A1

  公开（公告）日：2016-09-22

  Compounds of the formulas are provided: wherein variables Y 1 -Y 5 , X 1 -X 5 , A 1 -A 4 , X, y, n 1 , n 2 , and R 1 -R 15 are as defined herein. Pharmaceutical compositions of the compounds are also provided. In some aspects, these compounds are useful for the treatment of a disease or disorder, including, for example, a proliferative disease, such as cancer.

  提供以下化合物的公式：其中变量Y1-Y5，X1-X5，A1-A4，X，y，n1，n2和R1-R15如本文所定义。还提供了这些化合物的药物组合物。在某些方面，这些化合物可用于治疗疾病或疾病，包括例如增生性疾病，如癌症。